JNJ
JNJ
Indicative, may be delayed. Not trading-grade data.
Recently viewed
Only on this browser · up to 5Ticker detail
JNJ
Cached quote, historical USD prices, and attributed headlines.
AI-generated
AI overview
Latest JNJ headlines
- JNJ is mentioned among blue-chip dividend stocks in discussions about Roth IRA versus taxable accounts [2]. - It is listed as a potential stock to own if a bear market arrives [3]. - JNJ appears among dividend stocks recommended to buy and hold for the next five years [4].
Generated Nov 01, 2026 · 11:03 UTC
- Suze Orman Says You Don’t Have to Buy Every Market Dip. Here’s Why — Yahoo Finance
- Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep? — Yahoo Finance
- If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own — Yahoo Finance
- 5 Dividend Stocks to Buy and Hold for the Next 5 Years — Yahoo Finance
- 3 Biotech Stocks With Upside Of Up To 80% — Yahoo Finance
Summary of the linked headlines, not full-article analysis. AI can make mistakes; verify the sources. Not investment advice.
Some history or news is missing or stale. Available cached data remains visible; background requests respect provider retry backoff. Reload this range to check again.
Historical price
251 observations · USD · Source: Yahoo Finance · Oct 31, 2025 · 13:30 UTC to Oct 30, 2026 · 13:30 UTC · latest observation may be incomplete.
News about JNJ
- Suze Orman Says You Don’t Have to Buy Every Market Dip. Here’s Why ↗
- Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep? ↗
- If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own ↗
- 5 Dividend Stocks to Buy and Hold for the Next 5 Years ↗
- 3 Biotech Stocks With Upside Of Up To 80% ↗
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors. ↗
- Stryker Sinks 5% on Q3 Miss and Guidance Cut: “Fall Short of Our Expectations” ↗
- How Investors Are Reacting To Johnson & Johnson Stock New Drug Progress ↗
- No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust ↗
- Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the Difference ↗
- ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View ↗
- CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend. Which Should Retirees Choose? ↗
- 4 Dividend Kings With 50-Plus Years of Payout Increases for Retirement Income ↗
- JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? ↗
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards? ↗
- CFOs On the Move: Week ending Oct. 30 ↗
- What Sent Eli Lilly Stock Higher? ↗
- Has The Story Under Johnson & Johnson Stock Run Out? ↗
- Does Johnson & Johnson (JNJ) Have A New Edge In Plaque Psoriasis? ↗
- Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference ↗
Comments and bookmarks
Comments are plain text from NPDev accounts. Bookmarks stay private to the account that saved them.
No comments yet. Be the first to say something.
Sign in to join the conversation.